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Endometriosis is a multifactorial disease with poorly understood etiology, and reﬂecting an evolutionary nature where genetic
alterations accumulate throughout pathogenesis. Our objective was to characterize the heterogeneous pathological process using
parsimony phylogenetics. Gene expression microarray data of ovarian endometriosis obtained from NCBI database were polarized
and coded into derived (abnormal) and ancestral (normal) states. Such alterations are referred to as synapomorphies in a
phylogenetic sense (or biomarkers). Subsequent gene linkage was modeled by Genomatix BiblioSphere Pathway software. A
list of clonally shared derived (abnormal) expressions revealed the pattern of heterogeneity among specimens. In addition, it
has identiﬁed disruptions within the major regulatory pathways including those involved in cell proliferation, steroidogenesis,
angiogenesis, cytoskeletal organization and integrity, and tumorigenesis, as well as cell adhesion and migration. Furthermore, the
analysissupportedthepotentialcentralinvolvementofESR2intheinitiationofendometriosis.Thepathogenesismappingshowed
that eutopic and ectopic lesions have diﬀerent molecular biosignatures.
1.Introduction
In the USA, 10–20% of women suﬀer from endometriosis,
with 40% developing infertility. It is a public health issue
withapatient’smedicalcostsapproximately63%higherthan
those of the average woman [1]. The etiology and patho-
physiology of endometriosis remains poorly understood.
The hypothesis of retrograde menstruation is the oldest and
most widely accepted. However, it fails to explain why some
women develop endometriosis while others do not, given
thatso med egr eeo fr etr ograd eme n strualﬂo wi se xpe ri e n c ed
by all women [2]. Thus, other factors such as immunology
[3, 4], genetics [5], and the environment [6] may play a role
in the mechanism of disease development.
The genetic theory dates back to the ﬁrst formal genetic
study published in 1980 by Simpson et al. [5]. Numerous
ﬁndings since then support a polygenic multifactorial inher-
itance of endometriosis caused by an interaction between
multiple genes with the environment. Several studies from
the OXGENE (Oxford Endometriosis GENE) group con-
ﬁrmed an inheritance component to endometriosis. Speciﬁ-
cally,inone reportof100families withendometriosis from6
diﬀerent countries, 19 mother-daughter pairs and 56 sibling
pairs shared the disease [7].
A diagnostic method that screened for genetic proﬁles or
candidate genes may beneﬁt the patient by detecting disease
earlier, improving patient quality of life, discerning genetic
predisposition, lowering costs, and reducing the need for
invasive laparoscopic investigations.
Though not yet completely understood, numerous stud-
ies show a correlation between the occurrence of endo-
metriosis and ovarian cancer [8–10]. Both diseases share
pathogenic factors such as familial predisposition, genetic
modiﬁcations, immunologic abnormalities, uncontrolled
angiogenesis, and hormonal disturbances [11]. Malignant
transformationofendometriosishasbeenreported[2,12].It2 Obstetrics and Gynecology International
is hypothesized that ectopic glands may expand monoclon-
ally; however, this phenomenon is not yet clearly deﬁned
[13]. Elucidation of a cellular continuum from benign endo-
metriosis to malignancy requires more research and a greater
understanding of common mutational events.
Molecular processes involved in disease development
share aspects of evolutionary transformation such as genetic
mutations, clonal propagation, irreversible gene expression,
and shared derived genetic alterations. Sarnat and Netsky
ﬁrst put forth the concept of disease etiology by evolutionary
criteria in 1984 [14] whereby disease is viewed as an
accumulation of genetic mutations. In this study, we sought
toidentifyagenomicbiosignature(s)forendometriosisusing
a newly developed evolution-based parsimony phylogenetics
approach for gene expression microarrays data [15, 16]o f
endometriosis patients in order to stratify individual cases
based on the molecular change, model the disease based on
the level of patients’ gene expression proﬁles, and identify
aﬀected molecular pathways involved in the disease process.
2. Methods
Gene expression microarray datasets of endometriosis pa-
tients, GSE7305, from NCBI’s Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/) were used in
the study [17]. Brieﬂy, the datasets, submitted to NCBI
by Hever and colleagues and successfully published in the
P r o c .N a t l .A c a d .S c i .U S A[ 17], comprised 10 ovarian
endometriosis and 10 matched eutopic endometria from
the same patients using Aﬀymetrix Human Genome U133
Plus 2.0 gene array. Polarity assessment was carried out
using UNIPAL (Universal Parsing Algorithm) [18]b yc o d -
ing the expression values into ancestral (unchanged) and
derived (deregulated/abnormal) states. Unchanged values
were coded as zero (0) and altered/deregulated values as one
(1), thus transforming the original expression values into
a qualitative binary matrix of 0’s and 1’s [18]. Hierarchical
classiﬁcation through parsimony phylogenetic analysis was
carried out with MIX, the maximum parsimony program of
PHYLIPver.3.57ctoproducecladograms[19].TreeViewwas
used to redraw the cladogram for ﬁnal illustration [20].
Clonal alterations (or shared derived expression states,
named synapomorphies in the ﬁeld of phylogenetics or
biomarkers in the biomedical ﬁeld) were utilized to delimit
a natural group of related specimens, termed a “clade.” The
tree-likediagram,thecladogram,istheclassiﬁcationhypoth-
esis that models the relatedness between the specimens. The
full list of synapomorphies circumscribing the diseased spec-
imens was extracted and analyzed without ap r i o r iselection.
The analysis modeled the patterns of change occurring in the
gene expression data set, classiﬁed specimens, and mapped
the molecular events of altered pathways.
The synapomorphies were then modeled by Genomatix
BiblioSphere Pathway Edition software version 7.2 for gene
linkage. Genomatix BiblioSphere is data-mining software
that extracts and analyzes gene relationships from literature
databases (primarily NCBI PubMed) and genome-wide
promoter analysis. The Genomatix collection of gene names
and synonyms are supplied by NCBI Locust Link. We used
this program to model our synapomorphies to reveal gene
linkage and the aﬀected pathways of pathogenesis. The gene
maps have been ﬁltered with respect to abstract cocitation
level, B0.
3. Results
The maximum parsimony phylogenetic program, MIX, pro-
duced one most parsimonious cladogram (Figure 1(a)). The
cladogram has a directionality that reveals the amount
of accumulated shared derived (abnormal) expressions
from the base up (from eutopic endometrium to ectopic
endometriosis specimens). The endometriosis specimens
have the highest number of abnormal gene expressions.
The analysis revealed that all the endometriosis spec-
imens share 3,636 synapomorphies (or shared derived
(abnormal) gene expressions) that distinguish them from
the eutopic endometrium specimens. Synapomorphies are
additive and accumulate for specimens positioned higher
along the main axis of the cladogram. Thus, the addi-
tional 1,923 synapomorphies characterizing the highest
clade consisting of 4 specimens (GSM175766, GSM175767,
GSM175769, and GSM175770) share the greatest amount
of deregulated genetic information that is most spe-
ciﬁc to these four subjects. Within the directionality or
continuum of change, eutopic endometrium specimens
(GSM175783–85) that may be susceptible to developing
into endometriosis are located between the largest eutopic
endometrium clade (GSM175777–78) and ﬁrst endometrio-
sis clade (GSM175775). The cladogram identiﬁed transi-
tional patterns from eutopic endometrium (Figure 1(a)—
lower, green) to endometriosis (Figure 1(a)—upper, black)
specimens (GSM175783-85); these specimens separated
from the majority of eutopic endometrium specimens and
formed a transitional zone closer to the beginning of en-
dometriosis specimens’ clade. This analytical method can
graphically delineate and molecularly represent the progres-
sion of endometriosis through the accumulation of changes
in gene expression.
The modeling of gene expression heterogeneity is illus-
trated in the heat map in Figure 1(b). The heat map
depicts overexpressed (red), underexpressed (yellow), and
unchanged (green) gene expressions of 16 selected genes in
all ten endometriosis specimens and their relative expression
pattern per specimen, thus demonstrating the diﬀerential
expression of genes across specimens.
The expression of ZC3H15, taken as an example (Fig-
ure1(b), gene number 16), typiﬁes the heterogeneity of
single gene expression among the 10 endometriosis spec-
imens. Thus, among the endometriosis patients, ZC3H15
has a heterogeneous expression: while it is unchanged
in 4 specimens (GSM175766, GSM175774, GSM175768,
and GSM175773), it is overexpressed in GSM175769 and
underexpressed in 5 specimens (GSM175767, GSM175770,
GSM175772, GSM175771, and GSM175775). Furthermore,
the horizontal frame denotes the heterogeneity of several of
the 16 genes highlighted in the heat map even within two
specimens in close proximity on the cladogram that share a
multitude of synapomorphies.Obstetrics and Gynecology International 3
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Figure 1: Cladogram and a corresponding heat map of selected genes. (a) A most parsimonious cladogram depicting a hierarchical
classiﬁcationof10ectopicendometriosisand10matchedeutopicendometrialspecimensfromthesamepatients.Thenumberofclonalgene
expression aberrations is located at the crossing bar, and the directionality of change from eutopic endometrium to ectopic endometriosis
specimen is indicated by an arrow. The transitional zone is denoted by the asterisk. (b) Heat map of 16 selected genes corresponds to the 10
endometriosis specimens and exempliﬁes heterogeneous gene expression proﬁle of the endometriosis specimens. Synapomorphies are the
aberrant clonal gene expressions that are shared by the specimens placed at the nodal point (at the bifurcations). The cladogram models the
cumulative genetic change; it quantiﬁes the severity of molecular disruption and points out the direction of change accumulation along the
main axis of the cladogram in a hierarchical mode. The horizontal frame denotes the heterogeneity of the 16 genes highlighted within the
heat map for two of the specimens. Note that the heat map is arranged to line up directly with the corresponding endometriosis specimens
located on the adjacent cladogram.
The robustness of parsimony phylogenetics to model
genetic heterogeneity is further illustrated in Figure 2.L i p o -
calin 2 (LCN2) and MYB binding protein (P160, MYBBP1A)
are two examples of genes with dichotomous expression
(above and below their gene expression range of normal
specimens) as well as heterogeneity within the normal range
of gene expression (Figure 2(a)). MYBBP1A appears to be
tightly regulated as a slight deviation from the normal range
which seems to induce a pathological state (Figure 2(b)).
The functional and regulation relationships of the dif-
ferentially expressed genes were assessed using Genomatix
BiblioSphere (http://www.genomatix.com/). This analysis
focused on the 1,923 synapomorphic genes of the high-
est clade (GSM175766, GSM175767, GSM175769, and
GSM175770) to yield the greatest wealth of genomic insight
into the pathology of endometriosis. Groups of shared
derived genes were entered into Genomatix BiblioSphere
including underexpressed and overexpressed. We analyzed
the gene maps for prominent nodes as well as their central
and extended linkages.
Out of the 1,923 gene synapomorphies aforementioned,
583 overexpressed, coded in red (Figure 3(a) and full gene
listing in Supplemental Material (1) see Supplementary Ma-
terialsavailableonlineatdoi:10.1155/2011/719059)and459
underexpressed genes, coded in yellow (Figure 3(b) and full
gene listing in Supplemental Material (2)) were modeled.
The cladogram in Figure 1 shows a group of three in-
tandem specimens (GSM175783–85) that forms a transi-
tional zone between eutopic endometrium and ectopic en-
dometriosis. This clade was circumscribed by 707 synapo-
morphies. The pathway network analysis pointed out to
the overexpressed ERS2 as the central deregulated gene
aﬀecting other gene nodes (Figure 4). This pathway anal-
ysis showed that the gene network was also diﬀerent
from the lower clade of the eutopic endometrial speci-
mens (GSM175776, GSM175777, GSM175778, GSM175779,
GSM175780, GSM175781, and GSM175782) (Figure 5).
4. Discussion
Parsimony phylogenetics, an evolution-based bioinformatic
paradigm, revealed deregulated clonal expressions within
ectopic endometriosis as compared to eutopic endometrium
specimens. This analytical method achieved several goals:
construction of the molecular disease boundaries and4 Obstetrics and Gynecology International
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Figure 2: Parsimony phylogenetics identiﬁes expression heterogeneity of single genes. (a) LCN2 (lipocalin 2) and (b) MYBBP1A (MYB
binding protein (P160)) depict the dichotomous (under and over) gene expression as well as heterogeneity within the range of gene
expression of the specimens.
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Figure 3: Gene linkage map for the over- (a) and underexpressed (b) genes ﬁltered separately at the B0 level using Genomatix BiblioSphere.
Gene list was obtained from the 4 specimens (GSM175766, GSM175767, GSM175769, and GSM175770) at the upper end of cladogram in
Figure 1(a).
pathways’ aberrations, stratiﬁcation (subtyping) of disease,
detection of early disease stages, suggestion of potential
therapeutic targets, and identiﬁcation of the biosignature
(proﬁle) of diseased specimens.
The comprehensive parsimony phylogenetics analysis
revealed an extensive list of shared derived (deregulated/
abnormal) expression states—or synapomorphies in a phy-
logenetic sense (biomarkers in a biomedical sense), which
showed the extent of heterogeneity among specimens.
Furthermore, it identiﬁed dichotomously expressed asyn-
chronous genes (DEA) among endometriosis specimens
[16]; these are gene expression values that are above
and below the range of gene expression of the eutopic
endometrium specimens (Figure 1(b)). Each DEA gene
splits the specimens into two groups, thus showing the
heterogeneity that exists among endometriosis specimens.
This pattern was ﬁrst reported by Lyons-Weiler et al. [21]
and termed DEA by Abu-Asab et al. This phenomenon was
designated dichotomously expressed asynchronicity to reﬂect
its two-tailed distribution and deviation from the expression
range of the outgroup [16]. While F- and t-statistics as well
as fold change may not consider DEA genes signiﬁcant or
include them within the list of diﬀerentially expressed genes
[21], the polarity assessment algorithm assesses each value asObstetrics and Gynecology International 5
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Figure 4: Gene linkage map of the genes at the node of the
transitionalzone(marked byan asteriskin Figure 1(a))c o nstruct ed
by Genomatix BiblioSphere. The overexpressed genes coded in
red, underexpressed in yellow, and unchanged in green were all
combined and ﬁltered at the B0 ﬁlter level. The color coding reﬂects
the gene expression heterogeneity among specimens and the power
of parsimony phylogenetics to reveal the dynamic disease process.
The biosignature is centered around ESR2 as the potential major
player inﬂuencing the gene network and change to endometriosis.
either derived or ancestral, thereby revealing the gene’s status
in relation to the gene proﬁle of the outgroup [16].
LCN2 and MYBBP1A heterogeneous expression as DEA
genes illustrates the complexity of this disease. LCN2 is
known as a marker from benign to pre- and malignant
ovarian tumors and may be involved in progression of epi-
thelial ovarian malignancies. It is also an epithelial inducer
in Ras malignancies and a suppressor of metastasis [22].
Upregulated in ovarian cancer cells, it may be involved
in the progression of epithelial ovarian malignancies [23].
Our results showed that 4 specimens exhibited LNC2 over-
expression which could explain the risk of progression of
endometriosisfromabenigntomalignantconditioninsome
patients [13, 24].
MYBBP1A is a novel NF-kappaB corepressor of tran-
scription and DNA-directed polymerase activity [25]. As-
sociations between the p160 coactivator proteins and en-
docrine resistance have been described, involving the MAP
kinase eﬀector proteins Ets [26]. This corepressor gene
expressionappearstobetightlyregulatedasaslightdeviation
fromthenormalrangeappearstoinduceapathologicalstate.
4.1. Overexpressed Genes. From the list of overexpressed
genes, we selected to discuss only a few among those re-
ported in the literature as relevant to the pathogenesis of en-
dometriosis.
The endocrine-gland-derived vascular endothelial
growth factor (PROK1) has been shown to possess a para-
crine role for prokineticins and their receptors in endometri-
al vascular function [27]. Endometriotic implants require
neovascularization to proliferate and invade into ectopic
sites,andsuchangiogenicfactorsarecurrentlybeingtargeted
for novel medical therapeutics [28].
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Figure 5: Gene linkage map of the genes at the lower clade (see
Figure 1(a)) composed of seven endometrial eutopic specimens
(GSM175776–82) constructed by Genomatix BiblioSphere set at
the B0 ﬁlter level. The overexpressed genes coded in red, under-
expressed in yellow, and unchanged in green were all combined
and ﬁltered at the B0 ﬁlter level. The color coding reﬂects the
gene expression heterogeneity among specimens and the power of
parsimony phylogenetics to reveal the dynamic disease process. The
biosignatureiscenteredonCNR2andCASP3asthepotentialmajor
players inﬂuencing the gene network.
Caveolin-1(CAV1)hasbeenshowntonegativelyregulate
the Jak-2 tyrosine kinase in mice [29] and the latter modu-
lating the processes of cell proliferation, diﬀerentiation, and
apoptosis [30].
Nerve growth factor (NGF) levels are higher in the fol-
licular ﬂuid of women with endometriosis [31]. Histological
analysis of human deep innervating endometriosis (DIE)
tissue showed strong expression of NGF in endometriotic
glands and stroma of DIE which may play a role in the
pathways involved in the intense pelvic pain that patients
experience [32].
Hydroxysteroid (17-beta) dehydrogenase 11 (HSD17β-
11) converts 5 alpha-androstane-3 alpha, 17 beta-diol to
androsterone [33]. Expression analysis has revealed signif-
icant upregulation of enzymes involved in estradiol syn-
thesis (i.e., aromatase, sulfatase, and all reductive 17 beta-
HSDs), which indicates increased local levels of mitogenic
e s t r a d i o la n dd e c r e a s e dl e v e l so fp r o t e c t i v ep r o g e s t e r o n ei n
endometriosis [34].
4.2. Underexpressed Genes. BCL-2-related ovarian killer
(BOK) is a proapoptotic protein identiﬁed in the ovary [35]
and functions as an essential mediator of p53-dependent
apoptosis [36].
It is well established that the matrix metalloproteinase
system (MMPs) plays an important role in the normal6 Obstetrics and Gynecology International
Table 1: Gene list of over- and underexpressed genes summarized by function. These dichotomously expressed genes reﬂect the gene
expression heterogeneity among specimens.
Function Gene symbol
Cell cycle
CAV1 CCNA2 DDR2 E2F2 GPC3
GPC6 GTSE1 IFI16 MAD2L2 MAP2K6
NCAPH PTPN21 PTPN3 RBBP8 RPS6KA3
SLBP TGFBR3 TP53 TRMU
Cell adhesion and
migration
CDH1 CDH3 CLDN3 CLDN4 CLEC10A
HOXA10 HOXA11 HOXB2 HOXB3 HOXB4
HOXB5 HOXB6 HOXB7 HOXB8 HOXC4
HOXC5 HOXC6 IQGAP1 LGALS8 TGFBR3
Apoptosis
IHPK2 BIRC5 BNIP3L BOK FAIM3
IL24 MAP2K6 MAPK10 PAK6 RBMS3
TP53 TPD52L1 WDR26
Infertility/fertility LEFTY2 PAK6 SPA17 SPAG1
Immunity
BOC BST2 CD40 CEACAM1 CLEC10A
ICAM1 IGSF11 JAK3 NR3C1 PVRL3
RIPK2 SIGLEC1 SIGLEC11 TNFSF13B TSC22D3
Cell structure
ACTA2 ACTG2 ARHGAP25 ARL6IP5 CLDN5
CNKSR1 COL10A1 COL3A1 COL4A3 COL8A1
DCLK1 EMCN ESR1 HS6ST2 IQGAP1
ITGA11 ITGB8 KRT19 LAMA5 LAMB2
LAMC2 LAMC3 LTBP2 MMP26 NID2
PAK6 PCOLCE PPFIBP1 SGCE SIRPA
SPC25 SPTBN1 TGFBR3 TNS1 VAPA
Iron FTL
Angiogenesis/invasion
ADAMTS3 ANGPT1 ANGPTL1 C9ORF47 ITGA7
NRP1 NRP2 PROK1 S1PR3 TIMP1
TIMP4
Proliferation
ADAMTS18 CLDN11 CREG1 DOK5 DUSP4
EHF GPC6 IFI16 MAP3K1 MAPRE2
NTRK2 PTPRB TRAF4
Steroid hormone regulation
AKR1C1 AKR1C2 CPE CRYM CYP11A1
CYP2J2 CYP39A1 DIO2 ESR1 FST
HSD11B1 NR3C1 PLTP PTGER3 PTGFR
PTGIS RORA STAR VIPR2
Tumor suppressor DIRAS3 E2F2 FABP3 LYVE1 SMARCB1
Carcinogenesis
DOCK4 ERBB3 ESR1 FN1 HLA-C
JAZF1 IGK IGKC NBR1 RECK
TBX2
Stress response BDNF
development of the endometrium. MMPs have also been
implicated in the adhesive, invasive, and metastatic processes
involved in endometriosis [37]. Both ectopic and eutopic
endometrial tissues show altered levels of MMP and TIMP
expression, favoring tissue invasion and remodeling.
Tumor protein 53 (TP53) regulates the cell cycle func-
tions as atumor suppressorandwhileits role inendometrio-
sis remains unclear, there is evidence to support its apoptotic
resistance and enhanced survival of endometrial cells in
endometriosis [38]. TP53 was found to be overexpressed in
epithelial cells in a considerable number of endometriotic
lesions [39]. However, it was found that TP53 was insignif-
icantly upregulated in endometriosis tissue when compared
with control endometrium [40].
Estrogen plays a signiﬁcant role in the maintenance
and chronic bleeding of endometriosis. Estrogen receptor 1
(ESR1 or ERalpha) is the dominant receptor in the adult
uterus and the major mediator of estrogenic eﬀects. It playsObstetrics and Gynecology International 7
a role in the hormonal deregulation and inﬂammation seen
in this disease [41]. Steroid hormone receptors such as ESR
are altered in endometriosis [42, 43].
The analysis of the combined pathway of over- and un-
derexpressed genes, as summarized in Table 1, revealed that
tissue inhibitor of metallopeptidase 1 (TIMP1) may par-
ticipate in the process of invasion and tissue remodeling that
is hypothesized to occur in the pathogenesis of endometrio-
sis [44]. In endometrial carcinomas, Ephrin-B2 (EFNB2)
expression may reﬂect or induce increased potential for
growth and tumorigenicity [45].
Brain-derived neurotrophic factor (BDNF) levels are low
in the follicular ﬂuid of women with endometriosis and sug-
gest that neurotrophins may contribute to the pathogenesis
via aberrant oxidative stress mechanisms [31]. Shaco-Levy et
al. (2008) found that levels of CDH1, MMP-2, and MMP-
9 expressions were signiﬁcantly higher in endometriosis as
compared to endometrioid carcinoma, indicative of altered
cell proliferation, migration, diﬀerentiation, angiogenesis,
apoptosis, and host defense [46].
Increased levels of ﬁbronectin 1 (FN1) by peritoneal
macrophages in patients with endometriosis may contribute
to the adhesion formation and associated reactive ﬁbrosis
seen in this disease and may inﬂuence the implantation of
endometrial cells and their subsequent growth in the pelvis
[47].
Phosphoinositide-3-kinase and RAS/RAF/MAPK path-
ways have been suggested to be involved in the initial
development of endometriosis [48]. Intercellular adhesion
molecule 1 (ICAM1) may play a role in the early implanta-
tion of peritoneal endometriosis [49].
4.3. Transitional Zone. While the analysis of the upper clade
of the endometriotic specimens showed a particular biosig-
nature, the analysis of the lower clade, composed of eutopic
endometrial tissue of patients with endometriosis, revealed
twodistinctbiosignatures,onespeciﬁctothelowercladeand
the other to the transitional zone. Although diﬀerent sets of
genes were identiﬁed, they are also involved in the control of
inﬂammation, the immune response, apoptosis, cell prolifer-
ation, and lipid metabolism (Table 2). The chymase 1 gene
(CMA1) found in mast cells has been shown to inﬂuence
the inﬂammatory response by converting interleukin-1 beta
into the active form, interleukin 1 [50]. The prostaglandin-
endoperoxide synthase 2 gene (PTGS2/COX2) has been
reported to play an important role in the inﬂammatory
response through the production of prostaglandins [51].
Meanwhile, the cannabinoid receptor 2 (CNR2) has been
shown to play an anti-inﬂammatory and antioxidative role
in mice that have undergone chemotherapy [52].
Other studies have shown that member A of the Ras
homolog gene (RHOA) can inﬂuence cell apoptosis in
heart muscle cells [53]. The caspase 3 gene has also been
found to induce apoptosis in cells when overexpressed
[54], but possess a negative feedback mechanism as well to
prevent excessive and potentially harmful mass cell death
[55]. The other apoptosis-related gene is BAD; it could
induce apoptosis through cleavage by caspases or inhibit
apoptosis if the gene is overexpressed [56]. Finally, studies
have found that the ABCA1 gene plays a major role in
cholesterol transport across cell membranes [57]. This can
greatly aﬀect the synthesis of steroid hormones such as
estrogen, which is well known to possess a strong stimulating
eﬀect on endometriotic growth [58]. Among the gene
synapomorphies (biomarkers)identiﬁedis DRD2,whichhas
recently been linked to eutopic and ectopic endometriotic
lesionsandsuggestedasatargettodeveloptherapeutics[59].
4.4. Applications in Diagnosis and Prognosis. Expression
proﬁle of specimens at the border between eutopic endome-
trium and endometriosis specimens, interestingly, revealed
that the overexpressed estrogen receptor 2 (ESR2) is a central
linkage to other gene nodes. The transitional status of
these specimens is highlighted by the mostly dichotomously
expressed synapomorphies (Figure 4). This is an important
ﬁnding because it shows that the overexpression of ESR2
could be the triggering step that initiates the deregulation
of other key genes associated with inﬂammation, cellular
matrix, immune response, growth factors, apoptosis, and
others, thus leading to endometriosis (Supplementary Mate-
rial 3). Indeed, several studies have reported high expression
of ESR2 but lower levels of ESR1 in endometriotic tissue
which caused a decrease in ESR1/ESR2 ratio [41, 60, 61]
and which is in agreement with our ﬁndings (see also ESR1
in Figure 3). While Bulun and colleagues recently proposed
a hypothetical model where the strikingly low ratio of
ESR1/ESR2 could shift the stimulatory eﬀect of estradiol
on the progesterone receptor expression [62, 63], our study
showed that the overexpression of ESR2 could precede the
pathologicalandclinicalsignsofendometriosis;thesepoten-
tially at-risk specimens grouped together closer to diseased
specimens. The overexpression of ESR2 could be triggered
by several factors ranging from genetic predisposition [64]
to environmental exposures [65–67]. ESR2 polymorphism
has been reported to play a role in endometriosis in various
populations such as Brazilian [68] and Japanese women
[69]. The disruption of ESR2 and the ensuing decrease of
the ESR1/ESR2 ratio could be the culprit for the cascade
of molecular events that initiates cellular deregulation and
tissue remodeling associated with endometriosis (Figure 6).
The screening for increased ESR2 expression could oﬀer
a diagnostic tool to identify women at risk of developing
endometriosis.
It should also be noted that the endometrial tissue of
women with endometriosis is diﬀerent from the endometrial
tissue of healthy women without the disease. For example,
diﬀerences in proliferation of endometrial epithelial, stro-
mal, and endothelial cells [70, 71], spontaneous apoptosis
[72, 73], expression of cell adhesion molecules [74], and
production of steroids and cytokines [74, 75]h a v eb e e n
found. The limitation of our study is that we are restricted
by the original design of published studies as deposited in
the public domain. Although this dataset was limited to only
20 specimens, Hever and colleagues successfully published
their ﬁndings [17] and made them available. It is important
to note that endometriosis omics data available in the public
domain is limited.8 Obstetrics and Gynecology International
Table 2: Gene list summarizing the biosignature of the eutopic clade.
Function Gene symbol
Cell cycle CDKN2A PTGS2 EGFR MDM2 F2
BRCA2 BTRC
Clotting/vascular integrity F2 NOS1 RHOA MMP1 SP1
Cell adhesion and
migration
CD36 RHOA MMP1 EGFR CDKN2A
F2 JAG1 PTGS2
Apoptosis
MDM2 BAT3 BCL2L1 IL17A RARA
CASP3 BAD AKAP13 PTGS2 EGFR
CDKN2A F2 RHOA
Infertility/fertility MMP1 EGFR BRCA2 BCL2L1 PTGS2
Immunity
CD19 CD68 IL17A IL1RN RARA
CMA1 CDKN2A BAD CD36 CNR2
MMP1
Inﬂammation IL1RN IL17A CMA1 PTGS2 F2
CNR2
Cell structure KCNJ5 TPM3 RHOA EGFR F2
MMP1
Carcinogenesis TPM3 KLK3 EGFR
Angiogenesis/invasion JAG1 KLK3 PTGS2
Cell proliferation EGFR CDKN2A F2 BRCA2 MDM2
BTRC BAD BCL2L1 JAG1
Organogenesis SP1 TPM3 MMP1 EGFR BCL2L1
DRD2 JAG1
Steroid hormone regulation RARA RHOA
Tumor suppressor MDM2 BAT3 BRCA2 NOS1
Stress response FADS1 NOS1 RHOA
Protein ubiquitination BTRC MDM2
Lipid metabolism ABCA1 FADS1 PTGS2 CD36
Dopamine receptor DRD2
Ion transport KCNJ5 SP1 RARA DRD2 PTGS2
Glucose homeostasis BAD RHOA
Cell debris removal CD68 CD36
Water and ion balance DRD2
Cell diﬀerentiation FADS1 JAG1 SP1 RHOA
In summary, through this study, we have shown that the
biosignature of the endometriotic lesion is diﬀerent from
that of the endometrial eutopic tissue. Furthermore, we have
revealed a particular biosignature for specimens that are in
a transitional state to develop uterine endometriosis. This
study contributed a novel phylogenetic approach to mod-
eling the molecular heterogeneity of endometriosis patients
into a tree-like hierarchical cladogram that reveals the
simultaneously deregulated gene expressions—also termed
clonal or driver aberrations. This data-based analysis shows
not only directionality of change from eutopic endometrium
to ectopic endometriosis, but also its usefulness in categoriz-
ing specimens according to the accumulation of molecular
changes, which can be applied in diagnosing or for screening
patients at-risk for developing endometriosis. In addition
to supporting the ESR1 to ESR2 ratio hypothesis on the
initiation of endometriosis, we have shed light on new
genes and pathways that were not previously described as
signiﬁcant to the pathology of endometriosis. This work is
a necessary ﬁrst step in examining novel gene networks by
a biologically compatible method that could shed light on
principal drivers of the disease development process.
Glossary of Phylogenetics Terminology
UsedinThisPaper
Since the ﬁeld of phylogenetics, already extensively used
in biology, zoology, botany, virology, and parasitology for
over 50 years, is new to the biomedical ﬁeld, we think thatObstetrics and Gynecology International 9
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Proliferation
apoptosis
Abnormal
ECM and
cytoskeleton
Cell adhesion
Invasion
Inﬂammatory
response
Tissue
remodeling
Figure 6: Diagram summarizing the central role of ESR2 in
triggering the molecular cascade of cell and tissue dysfunction in
the transitional zone, which could lead to endometriosis.
providing a glossary would be useful to the reviewers and
readers.
Clade. A group of specimens sharing one or more synapo-
morphies.
Cladogram. Agraphicrepresentationofrelationshipsamong
specimens based on the synapomorphies (shared derived
characters).Thecladogramisasummaryoftrendsthatoccur
inthedatawhiletheupperpartofitrepresentsthespecimens
withhighestamountofsynapomorphies(sharedmutations).
Dynamic Classiﬁcation. A classiﬁcation that has the capacity
to incorporate new novel specimens without major alter-
ations to its main groups.
Outgroup. The group of specimens used to polarize the in-
group values of gene expression into ancestral (plesiomor-
phic) and derived (apomorphic).
Ingroup. The group of specimens under study, for example,
cancer specimens or endometriosis specimen in this study.
Parsimony. Means simplicity, the preferred hypothesis is the
one requiring the least number of explanations (Occam’s
Razor). In the context of our work, the preferred phyloge-
netic tree is the tree that requires the least number of steps to
construct it from the polarized data matrix.
Polarity Assessment. Also known as outgroup comparison. It
is the basis of sorting out the data values (whether proteomic
(m/z), or microarray expression values) into ancestral and
derived. By using our algorithms (UNIPAL/E-UNIPAL), we
transform absolute numbers from data values into polarized
binary numbers (0/1), where zero (0) signiﬁes ancestral and
one (1) signiﬁes derived.
Predictive Classiﬁcation. A classiﬁcation that reveals the
characteristics (or proﬁle/pattern) of a specimen when its
place in the classiﬁcation is known.
Phylogenetic Classiﬁcation [Phylogenetic Systematics]. A clas-
siﬁcation that uses synapomorphies to delimit clades (i.e.,
monophyletic groups).
Synapomorphy. A shared derived protein or gene expression
value in comparison with a number of normal specimens
(the outgroup). A protein synapomorphy may have one
of the following conditions: (1) a new novel protein, (2)
a disappeared protein, (3) up regulated protein, (4) down
regulated protein, and (5) asynchronously regulated protein
(the m/z values are above and below the normals’ range but
not within the normals’ range). A gene synapomorphy may
haveoneofthefollowingconditions: (1)overexpressedvalue
above normals’ range, (2) underexpressed value below the
normals’range,(3)dichotomouslyasynchronousvalues,and
(4) unmeasurable expression value.
Abbreviations
UNIPAL: Universal Parsing Algorithm
DEA: Dichotomously Expressed Asynchronous
genes.
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